palladium has been researched along with leuprolide in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Behar, RJ; Cantor, A; Chovnick, SD; Huff, W; Otheguy, J; Perez, R; Sharkey, J; Solc, Z | 1 |
| Arger, P; Arjomandy, B; Broderick, GA; Epperson, RD; Kassaee, A; Malkowicz, SB; Whittington, R | 1 |
| Behar, RJ; Cantor, A; Chovnick, SD; Donohue, M; Huff, W; Otheguy, J; Perez, R; Rabinowitz, R; Sharkey, J; Solc, Z; Steele, J; Webster, C | 1 |
| Lee, LN; Stock, RG; Stone, NN | 1 |
| Stock, RG; Stone, NN | 1 |
| Bissonette, E; Miller, N; Smolkin, ME; Theodorescu, D | 1 |
| Bissonette, EA; Copp, H; Theodorescu, D | 1 |
| Burri, RJ; Cesaretti, JA; Ho, AY; Stock, RG; Stone, NN | 1 |
1 review(s) available for palladium and leuprolide
| Article | Year |
|---|---|
Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Brachytherapy; Chemotherapy, Adjuvant; Flutamide; Follow-Up Studies; Humans; Leuprolide; Male; Middle Aged; Palladium; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radiotherapy Dosage; Radiotherapy, Conformal | 2002 |
1 trial(s) available for palladium and leuprolide
| Article | Year |
|---|---|
Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Brachytherapy; Chemotherapy, Adjuvant; Flutamide; Follow-Up Studies; Humans; Leuprolide; Male; Middle Aged; Palladium; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radiotherapy Dosage; Radiotherapy, Conformal | 2002 |
7 other study(ies) available for palladium and leuprolide
| Article | Year |
|---|---|
Outpatient ultrasound-guided palladium 103 brachytherapy for localized adenocarcinoma of the prostate: a preliminary report of 434 patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Ambulatory Care; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brachytherapy; Chemotherapy, Adjuvant; Flutamide; Follow-Up Studies; Humans; Leuprolide; Male; Middle Aged; Neoplasm Staging; Palladium; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Injuries; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Retrospective Studies; Treatment Outcome; Ultrasonography, Interventional | 1998 |
The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Brachytherapy; Combined Modality Therapy; Dose-Response Relationship, Radiation; Goserelin; Humans; Iodine Radioisotopes; Leuprolide; Male; Palladium; Prostatic Neoplasms; Radiopharmaceuticals; Ultrasonography, Interventional | 1999 |
Minimally invasive treatment for localized adenocarcinoma of the prostate: review of 1048 patients treated with ultrasound-guided palladium-103 brachytherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biopsy; Brachytherapy; Combined Modality Therapy; Flutamide; Humans; Leuprolide; Male; Middle Aged; Palladium; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Ultrasonography | 2000 |
Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation.
Topics: Adult; Aged; Analysis of Variance; Androgen Antagonists; Brachytherapy; Combined Modality Therapy; Follow-Up Studies; Goserelin; Humans; Iodine Radioisotopes; Leuprolide; Male; Middle Aged; Neoplasm Staging; Palladium; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Retrospective Studies; Risk; Treatment Failure | 2002 |
Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Brachytherapy; Combined Modality Therapy; Enzyme Inhibitors; Finasteride; Humans; Leuprolide; Male; Neoadjuvant Therapy; Neoplasm Staging; Palladium; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Risk Factors; Survival Rate; Testosterone; Treatment Outcome; Ultrasonography, Interventional | 2005 |
Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Brachytherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Humans; Leuprolide; Male; Middle Aged; Neoadjuvant Therapy; Palladium; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes | 2005 |
Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
Topics: Analysis of Variance; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biopsy; Brachytherapy; Flutamide; Follow-Up Studies; Goserelin; Humans; Iodine Radioisotopes; Leuprolide; Male; Nitriles; Palladium; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radiotherapy Dosage; Relative Biological Effectiveness; Tosyl Compounds; Treatment Failure | 2009 |